LP
Leap Therapeutics, Inc.
LPTX · NASDAQ
$0.77 -3.15% (-$0.03)
Market Cap $31.9M
P/E Ratio 9.62x
Div. Yield -
ROE 14.52%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
75 /100
Cheap P/S 152.42x
P/B 0.21x
P/E 9.62x
Growth
100 /100
Growing Book val. growth 41.10%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 7,335.88%
Op. margin 31,465.10%
FCF margin 43,395.20%
Quality
33 /100
Poor ROE 14.52%
ROA 9.40%
Asset turnover 0.00x
Debt
80 /100
Low Current ratio 35.56x
Int. coverage -2,637.45x
Net debt/EBITDA 0.22x
Stability
25 /100
Unstable EPS volatility 43.36%
Profitable years 1
Beta 0.09x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LPTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Douglas E. Onsi
Employees
52
Headquarters
Cambridge